



galileopharma

V

Galileo Pharmaceuticals, Inc.
5301 Patrick Henry Drive
Santa Clara, CA 95054
galileopharma.com

RECEIVED
CENTRAL FAX CENTER

NOV 25 2003

OFFICIAL

Facsimile Transmission

Date: 25 November, 2003

To: USPTO – Central Fax; PTO-1449 for Art Unit 1614
(703) 872-9306

From: Michelle Walker, Patent Agent
408 654 5830x179(voice)
408 654 5831 (fax)

Pages

Following is a supplemental IDS (PTO-1449 form) for Serial Number 10/630,170 which is being handled by Art Unit 1614.

The information in this facsimile should be treated as confidential and is intended only for the use of the addressee specified above. It should be safeguarded from disclosure to others. If the reader is not the intended recipient, you are hereby notified that retention, verbal disclosure, copying, or otherwise disseminating this information is strictly forbidden by federal, state and local law. If you receive this fax in error, please notify the sender and return all copies to the address above.

+ I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703) 872-9306 on November 25, 2003.

Typed or printed name of person signing this certificate:
Michelle Y. Walker, Agent No. 53,903

Signature:


November 25, 2003

RECEIVED
CENTRAL FAX CENTER

NOV 25 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

BODDUPALLI et al.

Attorney Docket No. 0118-CIP

Serial No. 10/630,170

Art Group: 1614

Filed: 07/30/2003

Examiner; not assigned

Title: FURANONE DERIVATIVES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmittal Letter for Supplemental Information Disclosure Statement

Applicants wish to bring to the attention of the Examiner an additional, recently published reference document. The attached Information Disclosure Statement is filed in compliance with 37 CFR §1.56, and the documents cited therein may be material to the examination of the subject Application.

This submission consists of:

- (a) This Transmittal Letter
- (b) Form 1449, "List of References Cited" with one U.S. Patent Document referenced

Certified Statement

This Supplemental Information Disclosure Statement is being submitted more than three months after the filing date and before the mailing date of the first office action on the merits. Applicants' attorney hereby certifies under 37 CFR 1.97(e)(2) that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a foreign counterpart application, or, to the undersigned Attorney's knowledge after making reasonable inquiry, was known to any person designated in §1.56(c) more than three months prior to the filing of the Statement. The fee, if any, is due under 37 CFR 1.97(c).

Information Disclosure Statement
Serial No.

Case

Page 2

Deposit Account Authorization

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 50-2247.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



Michelle Y. Walker
Agent for Applicants
Registration No. 53,903

Galileo Laboratories
5301 Patrick Henry Drive
Santa Clara, CA 95054
Telephone No. (408) 654-5830 ex. 179

Date: November 25, 2003

